High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
20.32M
-34.51%
-0.341
+10.08%
26.62M
-1.82%
-0.040
-86.67%
33.86M
-30.51%
-0.236
-886.67%
Estimates Revision
The market is revising Downward the revenue expectations for Zymeworks Inc. (ZYME) for FY2025, with the revenue forecasts being adjusted by -18.03% over the past three months. During the same period, the stock price has changed by 76.21%.
Revenue Estimates for FY2025
Revise Downward
-18.03%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+30.84%
In Past 3 Month
Stock Price
Go Up
+76.21%
In Past 3 Month
12 Analyst Rating
Wall Street analysts forecast ZYME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYME is 35.10 USD with a low forecast of 25.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 26.520
Low
25.00
Averages
35.10
High
42.00
Current: 26.520
Low
25.00
Averages
35.10
High
42.00
Citizens JMP
Outperform
initiated
$32
2025-12-03
New
Reason
Citizens JMP
Price Target
$32
2025-12-03
New
initiated
Outperform
Reason
Citizens JMP initiated coverage of Zymeworks with an Outperform rating and $32 price target. The company's first internally developed product candidate, zanidatamab, was approved by the FDA, the analyst tells investors in a research note. The firm thinks Zanidatamab's second approval in gastroesophageal adenocarcinoma, expected in the second half of 2026, has a high likelihood of success.
B. Riley
Buy
maintain
$30 -> $40
2025-11-21
Reason
B. Riley
Price Target
$30 -> $40
2025-11-21
maintain
Buy
Reason
B. Riley raised the firm's price target on Zymeworks to $40 from $30 and keeps a Buy rating on the shares. Zymeworks' shift to a royalty-aggregation strategy aims to optimize future de-risked cash flows from partnered programs and the potential partnering of ZW191 in 2026, the analyst tells investors in a research note. By retaining in-house R&D, acquiring royalties rather than assets, and diversifying therapeutic exposure, the company reduces binary risk while maintaining scientific rigor, with a strengthened leadership team enhancing prospects for attractive, risk-adjusted shareholder returns, the firm says.
Leerink
Outperform
maintain
$37 -> $40
2025-11-19
Reason
Leerink
Price Target
$37 -> $40
2025-11-19
maintain
Outperform
Reason
Leerink raised the firm's price target on Zymeworks to $40 from $37 and keeps an Outperform rating on the shares after the company announced a strategic transformation from a traditional biotech into a revenue-generating royalty aggregator. The firm reiterated its Outperform rating given current valuation and its belief that the full HERIZON GEA-01 presentation will be a favorable catalyst. Additionally, current zani royalties/milestones represents roughly $29 in the firm's model, suggesting the stock is undervalued on zani fundamentals alone, the analyst tells investors in a research note.
Stifel
Stephen Willey
Buy
maintain
$30 -> $40
2025-11-19
Reason
Stifel
Stephen Willey
Price Target
$30 -> $40
2025-11-19
maintain
Buy
Reason
Stifel analyst Stephen Willey raised the firm's price target on Zymeworks (ZYME) to $40 from $30 and keeps a Buy rating on the shares. The firm is updating its model to reflect partner Jazz Pharmaceuticals' (JAZZ) disclosure of statistically-significant and clinically-meaningful topline results from the Phase 3 HERIZON-GEA-01 trial and Zyme's more-granular disclosure of those near-term regulatory milestone payments that are now likely-to-be-triggered following the trial success, the analyst tells investors.
Wells Fargo
Eva Fortea Verdejo
Equal Weight
maintain
$17 -> $25
2025-11-19
Reason
Wells Fargo
Eva Fortea Verdejo
Price Target
$17 -> $25
2025-11-19
maintain
Equal Weight
Reason
Wells Fargo analyst Eva Fortea Verdejo raised the firm's price target on Zymeworks to $25 from $17 based on recent news, while keeping an Equal Weight rating on the shares. The firm thinks there is value in the partnership approach, but is cautious on the royalty-driven strategy beyond zani until it gets more clarity.
H.C. Wainwright
Buy
upgrade
$26 -> $32
2025-11-18
Reason
H.C. Wainwright
Price Target
$26 -> $32
2025-11-18
upgrade
Buy
Reason
H.C. Wainwright raised the firm's price target on Zymeworks to $32 from $26 and keeps a Buy rating on the shares. Ziihera plus chemotherapy and Ziihera plus Tevimbra and chemotherapy demonstrated "highly statistically significant" and clinically meaningful improvements in progression-free survival compared to the control arm, trastuzumab plus chemotherapy, the analyst tells investors in a research note. Given the data, the firm upped its probability of approval for Ziihera in first-line HER2+ gastroesophageal adenocarcinoma to 90% from 60%.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Zymeworks Inc (ZYME.O) is -27.40, compared to its 5-year average forward P/E of -3.72. For a more detailed relative valuation and DCF analysis to assess Zymeworks Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.72
Current PE
-27.40
Overvalued PE
14.99
Undervalued PE
-22.43
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
2.39
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
32.11
Undervalued EV/EBITDA
-27.33
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
19.20
Current PS
0.00
Overvalued PS
47.93
Undervalued PS
-9.53
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ZYME News & Events
Events Timeline
(ET)
2025-11-18
06:00:58
Zymeworks unveils $125 million share buyback initiative
2025-11-18
05:59:46
Zymeworks Unveils Strategic Plan to Enhance Cash Flows for Ziihera
2025-11-18
05:46:52
Zymeworks names Scott Platshon as interim chief investment officer
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/20251203052227_eef1cb2909873b53ed4186f59861858c.png)
Preview
3.5
12-03GlobenewswireZymeworks Highlights ZW251 Progress at ASCO GI Conference
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/newsfilter.png)
Preview
3.5
12-03NewsfilterZymeworks to Showcase ZW251 Clinical Progress at ASCO GI
Preview
1.0
11-24NewsfilterZymeworks to Participate in Upcoming Investor Conferences in Miami
Sign Up For More News
People Also Watch
FAQ
What is Zymeworks Inc (ZYME) stock price today?
What is Zymeworks Inc (ZYME)'s business?
What is the price predicton of ZYME Stock?
What is Zymeworks Inc (ZYME)'s revenue for the last quarter?
What is Zymeworks Inc (ZYME)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Zymeworks Inc (ZYME)'s fundamentals?
How many employees does Zymeworks Inc (ZYME). have?